A Randomised, Double-blind, Placebo-controled Parallel Group Efficacy and Safety Study of BI 1356 (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug Naive or Previously Treated (6 Weeks Washout) Type 2 Diabetic Patients With Insufficient Glycemic Control
收藏DataCite Commons2025-12-08 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00003511/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
To investigate efficacy, safety and tolerability of BI 1356 versus placebo
提供机构：
Vivli
创建时间：
2019-04-12
